Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. - Trial NCT06328179
Access comprehensive clinical trial information for NCT06328179 through Pure Global AI's free database. This phase not specified trial is sponsored by Huai'an First People's Hospital and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 34 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Huai'an First People's Hospital
Timeline & Enrollment
N/A
May 24, 2022
Dec 30, 2027
Primary Outcome
Overall response rate，ORR
Summary
This study is a clinical trial aimed at evaluating the efficacy and safety of the
 VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly
 diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities.
 
 This study includes the induction and consolidation phases of AML treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06328179
Non-Device Trial